Soluble TLR4 Decoy Proteins Block Endotoxin Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively reduce gastrointestinal inflammation in animals caused by bacterial endotoxin binding to its cellular receptors, leading to inefficient nutrient absorption and growth issues in the animal meat and aquaculture industries.
Innovation Solution
Administering antibodies or peptides that target the extracellular domain of TLR4 or CD14 to disrupt the signal transduction complex formation between endotoxin and its cellular receptors in the gastrointestinal tract, thereby reducing inflammation and enhancing growth and feed efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If endotoxin binds to TLR4 and CD14 receptors in the gastrointestinal tract, then inflammatory responses are activated, but this leads to tissue damage, gut wall thickening, and reduced nutrient absorption efficiency
Solution Approach 1:
The patent uses soluble recombinant proteins (TLR4 extracellular domain or CD14 extracellular domain) as intermediary substances that compete with cellular receptors for endotoxin binding. These soluble proteins act as decoys, binding endotoxin in the gastrointestinal lumen and preventing it from interacting with functional cell surface receptors, thereby blocking the inflammatory signaling cascade while maintaining the ability to detect and respond to endotoxin exposure
Solution Approach 2:
The invention converts the harmful effect of endotoxin-receptor binding into a beneficial outcome by using the natural binding affinity of endotoxin for TLR4/CD14 against itself. The soluble recombinant proteins exploit endotoxin's inherent binding properties to sequester it, transforming the pathogenic interaction into a protective mechanism that reduces gastrointestinal inflammation and improves animal health
2Productivity
If gastrointestinal inflammation is reduced through blocking endotoxin binding, then nutrient absorption and growth improve, but the complexity of administering and producing the antibody or peptide increases
Solution Approach 1:
The patent employs soluble recombinant proteins that can be produced relatively simply using recombinant DNA technology in expression systems such as bacteria or yeast. These proteins are administered orally or through feeding solutions, providing a cost-effective and scalable approach compared to complex antibody therapies. The proteins serve their protective function and can be replenished through regular administration in the feed or water
Solution Approach 2:
The soluble recombinant proteins are designed to be stable in the gastrointestinal environment and capable of self-binding to endotoxin without requiring complex delivery systems or administration protocols. The proteins naturally circulate in the gastrointestinal tract, continuously binding endotoxin as it is present, providing passive but effective protection without active control mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in improved gut health, increased growth rates, and enhanced feed efficiency in animals, reducing the need for antibiotics and minimizing tissue damage during gastrointestinal trauma.
Implementation Method 1
Administering antibodies or peptides that target the extracellular domain of TLR4 or CD14 to disrupt the signal transduction complex formation between endotoxin and its cellular receptors
Data Source
AI summary
A method for reducing gastrointestinal inflammation, enhancing growth, or improving feed efficiency in a human or non-human animal is disclosed. The method involves administering to the animal an agent that can reduce the formation of the signal transduction complex of endotoxin, TLR4 and CD14 on the cellular surface of a cell in the gastrointestinal tract of the animal. In a preferred embodiment, an antibody against the extracellular domain of TLR4 or CD14 is used to reduce the formation of the complex. A composition that contains the antibody and an ingestible carrier is also disclosed. Further disclosed is a method for producing a peptide for enhancing growth, improving feed efficiency, or both in a human or non-human animal.